A detailed history of Silvant Capital Management LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Silvant Capital Management LLC holds 35,040 shares of BMY stock, worth $1.86 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
35,040
Previous 35,460 1.18%
Holding current value
$1.86 Million
Previous $1.92 Million 24.3%
% of portfolio
0.07%
Previous 0.09%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

SELL
$40.25 - $52.99 $16,905 - $22,255
-420 Reduced 1.18%
35,040 $1.46 Million
Q1 2024

Apr 30, 2024

BUY
$47.98 - $54.4 $88,619 - $100,476
1,847 Added 5.49%
35,460 $1.92 Million
Q4 2023

Jan 25, 2024

SELL
$48.48 - $57.85 $211,227 - $252,052
-4,357 Reduced 11.47%
33,613 $1.72 Million
Q3 2023

Oct 24, 2023

SELL
$57.89 - $64.73 $90,018 - $100,655
-1,555 Reduced 3.93%
37,970 $2.2 Million
Q2 2023

Jul 25, 2023

BUY
$63.71 - $70.74 $141,117 - $156,689
2,215 Added 5.94%
39,525 $2.53 Million
Q1 2023

Apr 26, 2023

SELL
$65.71 - $74.53 $41,922 - $47,550
-638 Reduced 1.68%
37,310 $2.59 Million
Q4 2022

Jan 23, 2023

BUY
$68.48 - $81.09 $37,184 - $44,031
543 Added 1.45%
37,948 $0
Q3 2022

Nov 09, 2022

SELL
$0.13 - $76.84 $23 - $14,138
-184 Reduced 0.49%
37,405 $2.66 Million
Q2 2022

Aug 03, 2022

BUY
$72.62 - $79.98 $4,211 - $4,638
58 Added 0.15%
37,589 $2.92 Million
Q1 2022

May 05, 2022

SELL
$61.48 - $73.72 $25,452 - $30,520
-414 Reduced 1.09%
37,531 $2.76 Million
Q4 2021

Feb 07, 2022

SELL
$53.63 - $62.52 $79,962 - $93,217
-1,491 Reduced 3.78%
37,945 $2.37 Million
Q3 2021

Nov 08, 2021

SELL
$59.17 - $69.31 $403,894 - $473,110
-6,826 Reduced 14.76%
39,436 $2.35 Million
Q2 2021

Aug 03, 2021

SELL
$61.91 - $67.42 $44,884 - $48,879
-725 Reduced 1.54%
46,262 $3.09 Million
Q1 2021

May 11, 2021

SELL
$59.34 - $66.74 $75,005 - $84,359
-1,264 Reduced 2.62%
46,987 $2.99 Million
Q4 2020

Feb 05, 2021

SELL
$57.74 - $65.43 $48,905 - $55,419
-847 Reduced 1.73%
48,251 $3.02 Million
Q3 2020

Nov 09, 2020

SELL
$57.43 - $63.64 $667,049 - $739,178
-11,615 Reduced 19.13%
49,098 $2.96 Million
Q2 2020

Aug 11, 2020

SELL
$54.82 - $64.09 $201,792 - $235,915
-3,681 Reduced 5.72%
60,713 $3.57 Million
Q1 2020

May 13, 2020

SELL
$46.4 - $67.43 $54,102 - $78,623
-1,166 Reduced 1.78%
64,394 $3.59 Million
Q4 2019

Feb 10, 2020

SELL
$49.21 - $64.19 $2,460 - $3,209
-50 Reduced 0.08%
65,560 $4.21 Million
Q3 2019

Nov 12, 2019

SELL
$42.77 - $50.71 $398,188 - $472,110
-9,310 Reduced 12.43%
65,610 $3.33 Million
Q2 2019

Aug 09, 2019

SELL
$44.62 - $49.34 $292,305 - $323,226
-6,551 Reduced 8.04%
74,920 $3.4 Million
Q1 2019

May 10, 2019

SELL
$45.12 - $53.8 $142,804 - $170,277
-3,165 Reduced 3.74%
81,471 $3.89 Million
Q4 2018

Feb 06, 2019

SELL
$48.76 - $63.23 $113,903 - $147,705
-2,336 Reduced 2.69%
84,636 $4.4 Million
Q3 2018

Nov 07, 2018

SELL
$55.19 - $62.25 $737,503 - $831,846
-13,363 Reduced 13.32%
86,972 $5.4 Million
Q2 2018

Aug 13, 2018

SELL
$50.53 - $62.98 $55,987 - $69,781
-1,108 Reduced 1.09%
100,335 $5.55 Million
Q1 2018

May 09, 2018

BUY
$59.92 - $68.98 $6.08 Million - $7 Million
101,443 New
101,443 $6.42 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Silvant Capital Management LLC Portfolio

Follow Silvant Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silvant Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silvant Capital Management LLC with notifications on news.